Antisoma (LSE: ASM.L - news) shares could double if the ovarian cancer drug, R1549, is successful, and halve if it is not says the Independent. Given the probability of success, reckoned to be about 65%, that looks a gamble worth taking says the paper.

Antisoma plc

Directors' Share Dealing

9 June 2008, London, UK: Antisoma plc ("Antisoma" or the "Company")
(LSE: ASM; USOTC: ATSMY), the cancer drug developer, announces that
both Dr Barry Price, Chairman and Glyn Edwards, CEO, have purchased
ordinary shares of 1p each in the Company as follows:


+------------------------------------------------------------------------+
|Director |Date of |Amount |Price |Total amount |% of Company |
| |transaction |of shares |(p) |of |held |
| | |purchased | |shares held |following the|
| | | | |in the |transaction |
| | | | |Company | |
| | | | |following | |
| | | | |the | |
| | | | |transaction | |
|----------+-------------+-----------+-------+-------------+-------------|
|Dr Barry |06.06.2008 |100,000 |22.25 |743,077 |0.17% |
|Price | | | | | |
| | | | | | |
|----------+-------------+-----------+-------+-------------+-------------|
|Glyn |06.06.2008 |470,000 |21.25 |2,140,000 |0.48% |
|Edwards | | | | | |
+------------------------------------------------------------------------+

Have actually got back into this - looking good again.

Out of these and into SKP